As flu cases rise across parts of the United States, treatment options beyond the commonly prescribed Tamiflu are increasingly in focus. One such option is Xofluza, which can serve as an alternative antiviral therapy for those aged five and older, reports BritPanorama.
Health experts emphasize that antiviral medications such as Xofluza are most effective when administered within two days of flu symptom onset, underscoring the importance of timely access to a range of treatment options. Tamiflu, or oseltamivir, remains the go-to for many patients, though Xofluza is gaining traction due to its single-dose regimen and fewer side effects.
The US Centers for Disease Control and Prevention recommends four antiviral drugs to treat flu: Tamiflu, Xofluza, Relenza (zanamivir), and Rapivab (peramivir). Tamiflu is approved for individuals aged two weeks and older, effectively reducing flu incidence when taken as a preventive measure. On the other hand, Xofluza, a single-dose tablet, presents a promising alternative, particularly for those who may experience side effects with Tamiflu, such as nausea and vomiting, which occur in about 18% of users.
Patients should be aware that while Xofluza may cost nearly $200 without insurance, manufacturer coupons can alleviate the sticker shock. Notably, Tamiflu generally entails a more prolonged treatment regimen, requiring twice-daily doses over five days, whereas Xofluza effectively halts viral shedding in one day, potentially curbing transmission within households. Despite its increasing popularity, accessibility remains an issue; some pharmacies may not consistently stock Xofluza, inhibiting its widespread use.
Concerns have emerged regarding the influenza virus developing resistance to Xofluza. Dr. William Schaffner, an infectious disease expert, noted that around 10% of cases may witness such resistance. This apprehension contributes to the ongoing preference for Tamiflu among practitioners, aligned with established treatment conventions. Currently, Tamiflu is favored for hospitalized patients and those exhibiting severe symptoms.
In contrast, Xofluza shows improved effectiveness against influenza B, as noted by Dr. Tim Uyeki of the CDC. While this drug is not recommended during pregnancy or for patients with complex illnesses, it boasts benefits in terms of dosing and side effects. Expert consensus suggests that further research into combined antiviral therapies may yield additional insights, especially for those with severe influenza.
As the flu season progresses, the conversation around antiviral treatments remains vital, particularly with new variants circulating. While the landscape of flu treatment evolves, the focus firmly remains on patient outcomes and the efficacy of available therapies, ensuring that individuals receive the care necessary during this challenging season.
